Literature DB >> 25186558

T-cell immunotherapy: looking forward.

Jacqueline Corrigan-Curay1, Hans-Peter Kiem2, David Baltimore3, Marina O'Reilly1, Renier J Brentjens4, Laurence Cooper5, Stephen Forman6, Stephen Gottschalk7, Philip Greenberg2, Richard Junghans8, Helen Heslop7, Michael Jensen9, Crystal Mackall10, Carl June11, Oliver Press2, Daniel Powell11, Antoni Ribas12, Steven Rosenberg10, Michel Sadelain4, Brian Till2, Amy P Patterson1, Robert C Jambou1, Eugene Rosenthal1, Linda Gargiulo1, Maureen Montgomery1, Donald B Kohn12.   

Abstract

Mesh：

Year:  2014        PMID： 25186558      PMCID： PMC4435492          DOI： 10.1038/mt.2014.148

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  65 in total

1.  Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery.

Authors:  Rona M MacKie; Robin Reid; Brian Junor
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

2.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

3.  HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

Authors:  Jan-Inge Henter; Annacarin Horne; Maurizio Aricó; R Maarten Egeler; Alexandra H Filipovich; Shinsaku Imashuku; Stephan Ladisch; Ken McClain; David Webb; Jacek Winiarski; Gritta Janka
Journal:  Pediatr Blood Cancer       Date:  2007-02       Impact factor: 3.167

4.  Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

Authors:  James N Kochenderfer; Wyndham H Wilson; John E Janik; Mark E Dudley; Maryalice Stetler-Stevenson; Steven A Feldman; Irina Maric; Mark Raffeld; Debbie-Ann N Nathan; Brock J Lanier; Richard A Morgan; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

Review 5.  Hematopoietic stem cells for cancer immunotherapy.

Authors:  Eric Gschweng; Satiro De Oliveira; Donald B Kohn
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

6.  Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.

Authors:  Cor Hj Lamers; Stefan Sleijfer; Sabine van Steenbergen; Pascal van Elzakker; Brigitte van Krimpen; Corrien Groot; Arnold Vulto; Michael den Bakker; Egbert Oosterwijk; Reno Debets; Jan W Gratama
Journal:  Mol Ther       Date:  2013-02-19       Impact factor: 11.454

7.  Strategy escalation: an emerging paradigm for safe clinical development of T cell gene therapies.

Authors:  Richard Paul Junghans
Journal:  J Transl Med       Date:  2010-06-10       Impact factor: 5.531

8.  Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors:  Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

Review 9.  The promise and potential pitfalls of chimeric antigen receptors.

Authors:  Michel Sadelain; Renier Brentjens; Isabelle Rivière
Journal:  Curr Opin Immunol       Date:  2009-03-25       Impact factor: 7.486

10.  Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.

Authors:  Luca Gattinoni; Steven E Finkelstein; Christopher A Klebanoff; Paul A Antony; Douglas C Palmer; Paul J Spiess; Leroy N Hwang; Zhiya Yu; Claudia Wrzesinski; David M Heimann; Charles D Surh; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2005-10-03       Impact factor: 14.307
View more
  29 in total

1.  The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective.

Authors:  Richard P Junghans
Journal:  Cancer Gene Ther       Date:  2017-03       Impact factor: 5.987

Review 2.  CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.

Authors:  Jae H Park; Mark B Geyer; Renier J Brentjens
Journal:  Blood       Date:  2016-05-20       Impact factor: 22.113

Review 3.  Potential applications of nanoparticles in cancer immunotherapy.

Authors:  Yimei Jia; Abdelwahab Omri; Lakshmi Krishnan; Michael J McCluskie
Journal:  Hum Vaccin Immunother       Date:  2016-11-21       Impact factor: 3.452

4.  Next Steps in the CAR Journey of a Thousand Miles.

Authors:  Malcolm K Brenner
Journal:  Mol Ther       Date:  2017-09-20       Impact factor: 11.454

5.  Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products.

Authors:  Kenneth Cornetta; Lisa Duffy; Cameron J Turtle; Michael Jensen; Stephen Forman; Gwendolyn Binder-Scholl; Terry Fry; Anne Chew; David G Maloney; Carl H June
Journal:  Mol Ther       Date:  2017-09-12       Impact factor: 11.454

Review 6.  Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer.

Authors:  Cristina Gutierrez; Colleen McEvoy; Laveena Munshi; R Scott Stephens; Michael E Detsky; Joseph L Nates; Stephen M Pastores
Journal:  Crit Care Med       Date:  2020-01       Impact factor: 7.598

Review 7.  Towards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infection.

Authors:  Barna Dey; Edward A Berger
Journal:  Curr Opin HIV AIDS       Date:  2015-05       Impact factor: 4.283

Review 8.  Novel immunotherapies for hematologic malignancies.

Authors:  Michelle H Nelson; Chrystal M Paulos
Journal:  Immunol Rev       Date:  2015-01       Impact factor: 12.988

9.  Dihydrofolate Reductase and Thymidylate Synthase Transgenes Resistant to Methotrexate Interact to Permit Novel Transgene Regulation.

Authors:  David Rushworth; Amber Mathews; Amir Alpert; Laurence J N Cooper
Journal:  J Biol Chem       Date:  2015-08-04       Impact factor: 5.157

Review 10.  Nanotechnology-based immunotherapies to combat cancer metastasis.

Authors:  Yuping Zhao; Muhammad Bilal; Maimoona Qindeel; Muhammad Imran Khan; Kuldeep Dhama; Hafiz M N Iqbal
Journal:  Mol Biol Rep       Date:  2021-08-23       Impact factor: 2.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.